Search research articles
Contact Us
Filters
Showing results (351-360 of 393) with videos related to
Page
of 40
Sort By:
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
October 6, 2010
Immunologic escape after prolonged progression-free survival with epidermal growth factor receptor variant III peptide vaccination in patients with newly diagnosed glioblastoma
John H Sampson, Amy B Heimberger, Gary E Archer, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
April 16, 2017
Long-term Survival in Glioblastoma with Cytomegalovirus pp65-Targeted Vaccination
Kristen A Batich, Elizabeth A Reap, Gary E Archer, et al.
Blood
|
July 20, 2011
Monoclonal antibody blockade of IL-2 receptor α during lymphopenia selectively depletes regulatory T cells in mice and humans
Duane A Mitchell, Xiuyu Cui, Robert J Schmittling, et al.
Neuro-Oncology
|
December 15, 2010
Greater chemotherapy-induced lymphopenia enhances tumor-specific immune responses that eliminate EGFRvIII-expressing tumor cells in patients with glioblastoma
John H Sampson, Kenneth D Aldape, Gary E Archer, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
February 15, 2003
Phase II trial of temozolomide in patients with progressive low-grade glioma
Jennifer A Quinn, David A Reardon, Allan H Friedman, et al.
Oncoimmunology
|
June 7, 2018
Temozolomide lymphodepletion enhances CAR abundance and correlates with antitumor efficacy against established glioblastoma
Carter M Suryadevara, Rupen Desai, Melissa L Abel, et al.
Health Physics
|
October 2, 2015
Delayed Effects of Acute Radiation Exposure in a Murine Model of the H-ARS: Multiple-Organ Injury Consequent to <10 Gy Total Body Irradiation
Joseph L Unthank, Steven J Miller, Ariel K Quickery, et al.
Neuro-Oncology
|
January 15, 2015
A phase II, multicenter trial of rindopepimut (CDX-110) in newly diagnosed glioblastoma: the ACT III study
James Schuster, Rose K Lai, Lawrence D Recht, et al.
Neuro-Oncology
|
May 12, 2004
Phase 1 trial of irinotecan plus BCNU in patients with progressive or recurrent malignant glioma
Jennifer A Quinn, David A Reardon, Allan H Friedman, et al.
Neuro-Oncology
|
February 12, 2011
Clinical trial end points for high-grade glioma: the evolving landscape
David A Reardon, Evanthia Galanis, John F DeGroot, et al.
Page
of 40
Search research articles
Search
Showing results (351-360 of 393) with videos related to
Sort By:
Page
of 40
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
October 6, 2010
Immunologic escape after prolonged progression-free survival with epidermal growth factor receptor variant III peptide vaccination in patients with newly diagnosed glioblastoma
John H Sampson, Amy B Heimberger, Gary E Archer, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
April 16, 2017
Long-term Survival in Glioblastoma with Cytomegalovirus pp65-Targeted Vaccination
Kristen A Batich, Elizabeth A Reap, Gary E Archer, et al.
Blood
|
July 20, 2011
Monoclonal antibody blockade of IL-2 receptor α during lymphopenia selectively depletes regulatory T cells in mice and humans
Duane A Mitchell, Xiuyu Cui, Robert J Schmittling, et al.
Neuro-Oncology
|
December 15, 2010
Greater chemotherapy-induced lymphopenia enhances tumor-specific immune responses that eliminate EGFRvIII-expressing tumor cells in patients with glioblastoma
John H Sampson, Kenneth D Aldape, Gary E Archer, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
February 15, 2003
Phase II trial of temozolomide in patients with progressive low-grade glioma
Jennifer A Quinn, David A Reardon, Allan H Friedman, et al.
Oncoimmunology
|
June 7, 2018
Temozolomide lymphodepletion enhances CAR abundance and correlates with antitumor efficacy against established glioblastoma
Carter M Suryadevara, Rupen Desai, Melissa L Abel, et al.
Health Physics
|
October 2, 2015
Delayed Effects of Acute Radiation Exposure in a Murine Model of the H-ARS: Multiple-Organ Injury Consequent to <10 Gy Total Body Irradiation
Joseph L Unthank, Steven J Miller, Ariel K Quickery, et al.
Neuro-Oncology
|
January 15, 2015
A phase II, multicenter trial of rindopepimut (CDX-110) in newly diagnosed glioblastoma: the ACT III study
James Schuster, Rose K Lai, Lawrence D Recht, et al.
Neuro-Oncology
|
May 12, 2004
Phase 1 trial of irinotecan plus BCNU in patients with progressive or recurrent malignant glioma
Jennifer A Quinn, David A Reardon, Allan H Friedman, et al.
Neuro-Oncology
|
February 12, 2011
Clinical trial end points for high-grade glioma: the evolving landscape
David A Reardon, Evanthia Galanis, John F DeGroot, et al.
Page
of 40